Methods: Data were derived from Cancer Research Center database from 38 pure DCIS cases who had received intraoperative radiation therapy between 2012-2017. Intraoperative electron radiotherapy (IOERT) was performed according to Iran's intraoperative radiation therapy consensus.
Introduction
Ductal Carcinoma In Situ (DCIS), which has recently been renamed to Ductal Intraepithelial Neoplasia (DIN), refers to proliferating malignant cells within their normal site in ductal and lobular sections with no invasion through he basement membrane with an higher risk for subsequent Previously, mastectomy was the standard choice 3 for DCIS in all patients. Nowadays it has changed from radical mastectomy to other procedures that are less disfiguring, such as lumpectomy, followed by post-operative radiation and adjuvant hormonal 4, 10 therapy. Since DCIS is a heterogeneous lesion, a single therapeutic protocol is not quite effective for this lesion 4, and management protocols are determined based on the physician's judgement. Much of the controversy in management of DCIS is related to the fact that the survival rate of DCIS is about one hundred percent and there is no data yet demonstrating how the current treatment for DCIS 11, 12 directly affects its survival. Annual risk of local recurrence in DCIS patients who only undergo breast 12 conserving surgery is about 1-2%.
Relative Risk (RR) of invasive ductal carcinoma for intraductal hyperplasia without atypia is 1.5-2%, and with atypia is 4-5%. The RR of invasive ductal 8 carcinoma for DCIS is 8-10% , but the main problem is the lack of distinction between the three grades of DCIS (low, intermediate and high) with regards to the relative risk.
Consideration of DCIS as a specific disease, gradually happened in the first half of the twentieth 3, 4 century. Due to a lack of invasion through the basement membrane in DCIS, it is classified as a nonlethal type of cancer and a precursor to invasive breast cancer.
Previously According to a contemporary cohort study conducted by the Mayo Clinic, the 12 year follow-up RR for Atypical Ductal Hyperplasia (ADH) in developing breast cancer is about 20.4% and after 25 9 years this RR increases up to 29%.
The risk of axillary metastasis in DCIS is less than 4%, thus, axillary lymph node dissection is not 4 , 6 necessary to be done. Although cytotoxic chemotherapy is not indicated in the treatment of 4, 6 DCIS , patients may benefit from hormonal therapy. Five years of hormonal therapy in patients with positive estrogen receptor results in a 30% reduction in the relative risk of local recurrence.
The natural history of DCIS is related to its 13 pathologic grade. High grade lesions and positive or close surgical margins are two important 6 predictive factors in DCIS recurrences.
Accelerated partial breast irradiation (APBI) is an alternative method for whole breast irradiation, which limits the exposure only to normal breast tissue areas. Intraoperative radiation therapy is a method of Accelerated Partial Breast Irradiation (APBI) where the whole dose of radiation is delivered to the identified tissue at the time of 15 surgery and before the wound site is closed. It seems that this method of radiation therapy increases the patient's compliance and satisfaction.
The National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B06 showed a 43% recurrence rate in patients treated with local excision alone, half of which were invasive recurrences. The addition of radiation and careful cytological review of margins significantly 4 improved the local control. In the NSABP B17 trial, the adjuvant radiation therapy decreased the rate of 4 ' , 6, 14 ipsilateral local recurrence about 60%.
Although the benefit of post-operative radiotherapy is shown, some of the patients did not receive adjuvant radiotherapy due to their lack of compliance, aging, the distance between radiotherapy center and 15 duration of the radiotherapy course.
According to the IRAN IORT consensus IRIOeRT (the society of Islamic Republic of Iran IOeRT) criteria (table 1) , patients received either the radical dose (21 Gy) radiotherapy or the boost dose (12 Gy) to the tumor bed during surgery. Four patients, who
Methods
Many patients who were unable to complete the six week course of radiotherapy, chose radical 17 mastectomy , even if the exposure access is easy. If it is shown that one session of intraoperative radiotherapy is equally as effective as standard radiotherapy, this problem would be resolved. IORT 18, 19 may be effective for selective patients after BCS. There is limited data on the efficacy of IORT in the 17, 18 management of DCIS. In this study, we evaluated the recurrence rate as DCIS or invasive breast cancer in patients with DCIS who had undergone BCS and IORT.
According to the TARGIT-A study, intraoperative radiation therapy (IORT) is a great choice 16 for certain women with early stage breast cancer.
This study was done between 2012 and 2017 at the Cancer Research Center of Shahid Beheshti University of Medical Sciences, Tehran, Iran. A total of 38 patients with pure DCIS and with DCIS and Paget's disease of breast were treated with breast conserving surgery and IORT at Khatam-Ol-Anbia Hospital, Tehran, Iran. Patient factors recorded included age, age at diagnosis, tumor size, tumor histologic grade, marital status, family history, tumor differentiation, sentinel and axillary lymph node status, surgical margins, estrogen and progesterone receptor status and whether hormonal therapy was received by patients or not.
The median number of lymph nodes extracted per patient was 1 (range 0 -12). High grade DCIS was reported in 65.7% cases, with 47.3% necrosis. Estrogen Receptor (ER) and Progesterone Receptor (PR) were positive in 68.4% and 50% respectively. Ki-67 as proliferative index was about 20% or more in 42.1% and in 28.9% of cases, was unknown. The lesion types are described in table 2.
Results
IORT as boost dose was delivered to 5 patients (13.6%) and one (20%) of them had recurrence later Tumor-free surgical margins were confirmed by pathology in 97.3% of cases, except in one patient in whom deep margins were involved. Lymph nodes extracted as sentinel lymph node were negative in patients who underwent this surgery.
Breast conserving surgery was performed on all of the 38 patients. Patients' age had a median of 55 years (range 33-76) and the histological size had a median of 1.8 cm (range 0. 3 -5) . It is notable that in 8 cases, the exact size of the mass could not be determined by the pathologist. Family history was positive in 23% of cases, and 11.11% in a first-degree family member.
were candidates for boost radiotherapy, had received radical radiotherapy due to their problems with access to and distance from the radiotherapy center. One of our patients was under 40 years old who had requested IRIOeRT for her treatment. The initial goal of the study was the assessment of ipsilateral breast DCIS or cancer recurrence status. Assessing the overall survival rate of patients was the secondary goal.
Hormonal therapy was prescribed in 42.1% of patients. Tamoxifen and letrozole were used in 66.6% and 33.3% of the patients respectively and none of the patients received chemotherapy.
Distant metastases and mortality were not observed in the studied patients and all patients were alive.
on. The patient with recurrence had extensive retro areolar micro calcification. Radiotherapy dosed at of 16 Gy was delivered to the nipple-areole complex. Furthermore, IORT as radical dose was delivered to 31 (81.5%) patients, with a recurrence rate of 12.9% (4 cases). Overall, local recurrence was documented in 5 cases (13.1 % of patients) with the mean follow up of 31 months (range 8-56 months) and mean age of 50 years. The pathology of recurrence was reported as DCIS in 3 cases and invasive breast cancer in the remaining two.
Mastectomy and immediate reconstruction were performed in 4 of the cases with a recurrence and simple mastectomy was done in the remaining one case.
All five patients with recurrence had tumor-free margins in previous pathology reports (table 3) . Average tumor size was 1.9 cm (range 0.7-4 cm). Four patients had high grade lesions and one patient had a low-grade lesion without necrosis. Comedonecrosis was observed in 3 cases. The case with low grade lesion had close superficial margins. The first pathology report of 3 of the cases were pure DCIS, one with DCIS and LCIS and the other, DCIS with Paget's disease. All extracted lymph nodes were negative. Four cases with recurrence received full radiotherapy and one patient received boost IORT plus external radiotherapy. Four patients had positive ER/PR receptor status. Ki-67 marker in 2 of the 5 patients with recurrence was over 20%. Moreover, two patients had positive family history and 4 of them had received hormonal therapy. Table 3 demonstrated the characteristics of the patient and tumor. DCIS is a heterogeneous disease. The treatment strategy is controversial due to its excellent 3 prognosis. The main purpose of treatment is to choose a management plan which reduces local recurrence and does not create unnecessary morbidity.
According to literature, most local recurrences of DCIS are in the lumpectomy cavity. It seems that intraoperative radiation to tumor bed proves to be sufficient for selected cases and local treatment can be completed in one session to increase the patient's compliance.
Discussion
Breast conserving surgery with or without adjuvant radiotherapy are the treatments of choice for DCIS; however, it depends on the size of lesion, grading and margin status. The recurrence rate in ipsilateral breast decreased by 50% in DCIS patients when administering radiotherapy after breast- 14 conserving surgery.
Although the women who had received intraoperative radiation therapy had higher rates of local recurrence , data on the effectiveness of IORT in DCIS patients is not adequate.
In a study conducted by Solin et al., it was shown that the 12-year rate of developing an ipsilateral breast event for DCIS cases who had been treated with excision without radiation was 14.4% and for patients with low-or intermediate-grade lesions, 2.5 cm or less in size and 24.6%
highfor patients with grade DCIS, 1 cm or less in size. The 12-year rate of developing invasive breast cancer for DCIS cases created with excision without radiation was 7.5% and 13.4% low , respectively for the or intermediate grade lesions, 2.5 cm or less in size and high grade lesions, 1 cm or less in size.
A study conducted by Donker et al. evaluated recurrence rate and outcomes during a 15-years follow up in DCIS patients who had undergone breast conserving surgery with or without radiotherapy, from the EORTC 10853 Randomized Phase III trial. This study showed that development of a local recurrence was seen in almost one in three non-irradiated women after local excision for DCIS. Radiotherapy nearly halved the risk of local recurrence.
Polgár et al. reviewed a retrospective series of 10,194 patients. The 10-year rate of local recurrence with and without radiotherapy were 9 -28% and 22-54% respectively. In four large randomized controlled trials (NSABP-B-17, EORTC-10853, UKCCCR, Swe DCIS; 4,568 patients,), 50 Gy whole-breast radiotherapy significantly decreased the 5-year local recurrence rate from 16 -22% to 7 -10% respectively. In a recent meta analysis of randomized trials, Polgár concluded that addition of radiotherapy to breast conserving surgery reduces the 22 risk of both invasive and in situ recurrences by 60%. In conclusion, There is not enough data on the effectiveness of IORT in DCIS management. Although there is not a large number of cases in our study, the finding of this study showed 13.1 percent local recurrence in a median follow up of 31 months. There was no involvement in the contralateral breast, distant metastasis or death in the study population., distant metastasis, or death. Further studies with more cases and longer follow up periods are needed for better evaluation of the effectiveness of IORT in management of DCIS.
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DCIS were successfully treated with BCS and IORT alone, only 2 cases from 35 patients suffered local recurrence of cancer after DCIS, with median follow-up of 42 months (range of 2 -83 months). The primary pathology of one of the cases was high grade DCIS and the other was intermediate grade DCIS, resulting in a 5.7% local recurrence rate in patients with DCIS who had undergone BCS and IORTwithout any deaths or distant recurrences.
In a study by Rashtian et al., DCIS patients were treated with BCS and IORT. The median follow-up was 18.3 months and only one patient suffered local recurrence, the primary histology was high grade DCIS. The 3-year actuarial local control rate was 19 93.3%.
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